It is further noteworthy that factors that promote LTCC support of DA release such as male sex, α‐synuclein, DAT and the absence of Calb1 correspond to risk factors for parkinsonian degeneration, understanding how these factors interact may allow the stratification of patient cohorts to identify those who would most benefit from targeting LTCC as a neuroprotective strategy with isradipine (Parkinson Study Group STEADY‐PD III Investigators, 2020). This evidence concerns the gene SLC6A3 and Parkinson disease.